Among them, UST has been approved for clinical usage in individuals with IBD, and Risankizumab has been recently approved for the treatment of moderate-to-severe active CD; the clinical remission rate in patients with moderate to severe CD treated with Risankizumab is 40%–45%, with an endoscopic remission rate of 29%–40% (45), whereas the remaining IL-23–specific inhibitors are currently undergoing tested at different stages (46, 47). This evidence concerns the gene IL23A and Cowden disease.